Nkarta, Inc.
NKTX evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Market Cap:
- $208.4M
- Lead Asset:
- nkx019 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for NKTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NKTX
Nkarta, Inc. (NKTX) is a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, primarily targeting autoimmune diseases and oncology indications.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for Nkarta, Inc..
Nkarta, Inc. (NKTX) is a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, primarily targeting autoimmune diseases and oncology indications.
- Nkarta is advancing NKX019, a CD19-directed CAR NK cell therapy, in Phase 1/2 trials for autoimmune diseases including lupus nephritis and systemic sclerosis [pipeline].
- The company reported a cash balance of $243.2 million as of June 30, 2026, expected to fund operations into 2029 [news · published 2026-08-10].
- Initial clinical data from autoimmune programs (myositis, scleroderma, program-wide safety) are expected at ACR 2026 in November [news · published 2026-09-27].
- Nkarta has a preclinical candidate NKX070 targeting CD70 in solid and liquid tumors, developed in collaboration with CRISPR Therapeutics AG [pipeline].
- The company reported a net loss of -$40.4M for the period ending June 30, 2026, with shareholders' equity of $247.7M [sec].
What works
- Nkarta has a strong cash runway of $243.2 million as of June 30, 2026, expected to fund operations into 2029, providing financial stability for ongoing trials [news · published 2026-08-10].
- The company is generating initial clinical data from multiple autoimmune programs (myositis, scleroderma) with a planned presentation at ACR 2026, indicating progress in a high-potential therapeutic area [news · published 2026-09-27].
- NKX019 has shown robust pathogenic B-cell depletion in autoimmune disease models, as presented at ACR 2025, supporting its mechanism of action [news · published 2025-10-22].
What to weigh
- Nkarta reported a net loss of -$40.4M for the period ending June 30, 2026, reflecting ongoing operational costs without approved product revenue [sec].
- The company discontinued NKX019 for relapsed/refractory non-Hodgkin lymphoma, pivoting to autoimmune disorders, which may delay potential oncology revenue [news · published 2026-09-03].
- NKX019 faces competition from autologous CD19 CAR T-cell therapies in autoimmune indications, as well as from other cell therapy developers like Juno Therapeutics (Bristol-Myers Squibb) [pipeline][competitor_trial].
From the filings
Quoted directly from source documents.
Nkarta expects to present initial clinical data from autoimmune programs at ACR 2026.
“Nkarta plans to present initial clinical data from autoimmune programs at ACR 2026.”
News · September 27, 2026
Cash balance of $243.2 million as of June 30, 2026, expected to fund operations into 2029.
“Cash balance of $243.2 million on June 30, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029”
News · August 10, 2026
NKX019 is a CD19-directed CAR NK cell therapy targeting autoimmune diseases.
“CD19-directed CAR NK cell therapy targeting CD19-positive B cells to eliminate pathologic B cells that produce autoantibodies”
Risks & what to watch (3)›
Key risks
- No approved products — Nkarta has no approved products and reported a net loss of -$40.4M as of 2026-06-30 [sec].
- Pipeline pivot uncertainty — Discontinuation of NKX019 for r/r NHL and pivot to autoimmune indications introduces execution risk [news · published 2026-09-03].
- Competitive landscape — NKX019 faces competition from autologous CD19 CAR T-cell therapies and other cell therapy developers [pipeline][competitor_trial].
What to watch
- Initial clinical data from NKX019 in autoimmune indications at ACR 2026 in November [news · published 2026-09-27].
- Enrollment progress and data from Ntrust-1 and Ntrust-2 trials at the 4 billion cell dose level [news · published 2026-08-10].
- Financial updates and cash runway status in future quarterly reports [news · published 2026-08-10].
Sources: Catalysts · Competitor trials · News · Pipeline · Generated October 9, 2026 · How we verify sources →
Run Nkarta, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nkarta, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.36 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 9.3%
- Days to cover
- 5.6
- Shares short
- 5,272,916
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NKTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Nkarta, Inc.?
Nkarta, Inc. (NKTX) is a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, primarily targeting autoimmune diseases and oncology indications.
What is Nkarta, Inc.'s lead drug candidate?
Nkarta, Inc.'s most advanced tracked candidate is nkx019 (Phase 1/Phase 2) for Lupus Nephritis; Systemic Sclerosis; Lymphoma, Non-Hodgkin.
Who is the CEO of Nkarta, Inc.?
Mr. Paul J. Hastings is the chief executive officer of Nkarta, Inc. (NKTX).
Where is Nkarta, Inc. headquartered?
Nkarta, Inc. (NKTX) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Nkarta, Inc. focus on?
Nkarta, Inc. develops therapies across Oncology, Gene Therapy, Immunology, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.